These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 31980175)

  • 21. Abl kinase regulation by BRAF/ERK and cooperation with Akt in melanoma.
    Jain A; Tripathi R; Turpin CP; Wang C; Plattner R
    Oncogene; 2017 Aug; 36(32):4585-4596. PubMed ID: 28368422
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery of Selective Small Molecule Degraders of BRAF-V600E.
    Han XR; Chen L; Wei Y; Yu W; Chen Y; Zhang C; Jiao B; Shi T; Sun L; Zhang C; Xu Y; Lee MR; Luo Y; Plewe MB; Wang J
    J Med Chem; 2020 Apr; 63(8):4069-4080. PubMed ID: 32223235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. T-Type Calcium Channels as Potential Therapeutic Targets in Vemurafenib-Resistant BRAF
    Barceló C; Sisó P; Maiques O; García-Mulero S; Sanz-Pamplona R; Navaridas R; Megino C; Felip I; Urdanibia I; Eritja N; Soria X; Piulats JM; Penin RM; Dolcet X; Matías-Guiu X; Martí RM; Macià A
    J Invest Dermatol; 2020 Jun; 140(6):1253-1265. PubMed ID: 31877318
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A signal transduction pathway from TGF-β1 to SKP2 via Akt1 and c-Myc and its correlation with progression in human melanoma.
    Qu X; Shen L; Zheng Y; Cui Y; Feng Z; Liu F; Liu J
    J Invest Dermatol; 2014 Jan; 134(1):159-167. PubMed ID: 23792459
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oncogenic BRAF(V600E) promotes stromal cell-mediated immunosuppression via induction of interleukin-1 in melanoma.
    Khalili JS; Liu S; Rodríguez-Cruz TG; Whittington M; Wardell S; Liu C; Zhang M; Cooper ZA; Frederick DT; Li Y; Zhang M; Joseph RW; Bernatchez C; Ekmekcioglu S; Grimm E; Radvanyi LG; Davis RE; Davies MA; Wargo JA; Hwu P; Lizée G
    Clin Cancer Res; 2012 Oct; 18(19):5329-40. PubMed ID: 22850568
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rescue of cell cycle progression in BRAF
    Toress-Collado AX; Nazarian R; Jazirehi AR
    Tumour Biol; 2017 Sep; 39(9):1010428317721620. PubMed ID: 28936920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
    Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
    Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
    Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
    Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Copper Chelation Inhibits BRAF
    Brady DC; Crowe MS; Greenberg DN; Counter CM
    Cancer Res; 2017 Nov; 77(22):6240-6252. PubMed ID: 28986383
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination Treatment with the BRAF
    Jeong JH; Oh JM; Jeong SY; Lee SW; Lee J; Ahn BC
    Thyroid; 2019 Apr; 29(4):540-548. PubMed ID: 30869573
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E-dependent role of autophagy in uveal melanoma.
    Zhao Y; Wang W; Min I; Wyrwas B; Moore M; Zarnegar R; Fahey TJ
    J Cancer Res Clin Oncol; 2017 Mar; 143(3):447-455. PubMed ID: 27928645
    [TBL] [Abstract][Full Text] [Related]  

  • 35. M-CSF as a therapeutic target in BRAF
    Barceló C; Sisó P; de la Rosa I; Megino-Luque C; Navaridas R; Maiques O; Urdanibia I; Eritja N; Soria X; Potrony M; Calbet-Llopart N; Puig S; Matías-Guiu X; Martí RM; Macià A
    Br J Cancer; 2022 Oct; 127(6):1142-1152. PubMed ID: 35725813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
    Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
    Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells.
    Jenkins MH; Croteau W; Mullins DW; Brinckerhoff CE
    Matrix Biol; 2015 Oct; 48():66-77. PubMed ID: 25989506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma.
    Ferrari de Andrade L; Ngiow SF; Stannard K; Rusakiewicz S; Kalimutho M; Khanna KK; Tey SK; Takeda K; Zitvogel L; Martinet L; Smyth MJ
    Cancer Res; 2014 Dec; 74(24):7298-308. PubMed ID: 25351955
    [TBL] [Abstract][Full Text] [Related]  

  • 39. EGFR/uPAR interaction as druggable target to overcome vemurafenib acquired resistance in melanoma cells.
    Laurenzana A; Margheri F; Biagioni A; Chillà A; Pimpinelli N; Ruzzolini J; Peppicelli S; Andreucci E; Calorini L; Serratì S; Del Rosso M; Fibbi G
    EBioMedicine; 2019 Jan; 39():194-206. PubMed ID: 30611716
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of oncogenic BRAF activity by indole-3-carbinol disrupts microphthalmia-associated transcription factor expression and arrests melanoma cell proliferation.
    Kundu A; Quirit JG; Khouri MG; Firestone GL
    Mol Carcinog; 2017 Jan; 56(1):49-61. PubMed ID: 26878440
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.